WallStSmart

Bloom Energy Corp (BE)vsVertex Pharmaceuticals Inc (VRTX)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Vertex Pharmaceuticals Inc generates 493% more annual revenue ($12.00B vs $2.02B). VRTX leads profitability with a 32.9% profit margin vs -4.4%. VRTX appears more attractively valued with a PEG of 2.19. VRTX earns a higher WallStSmart Score of 66/100 (B-).

BE

Hold

35

out of 100

Grade: F

Growth: 6.7Profit: 3.5Value: 4.0Quality: 5.3
Piotroski: 3/9Altman Z: -0.52

VRTX

Strong Buy

66

out of 100

Grade: B-

Growth: 8.0Profit: 9.0Value: 10.0Quality: 8.0
Piotroski: 3/9Altman Z: 3.62
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for BE.

VRTXUndervalued (+39.5%)

Margin of Safety

+39.5%

Fair Value

$716.04

Current Price

$433.07

$282.97 discount

UndervaluedFair: $716.04Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

BE1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
35.9%10/10

Revenue surging 35.9% year-over-year

VRTX6 strengths · Avg: 9.5/10
Profit MarginProfitability
32.9%10/10

Keeps 33 of every $100 in revenue as profit

Operating MarginProfitability
39.6%10/10

Strong operational efficiency at 39.6%

Altman Z-ScoreHealth
3.6210/10

Safe zone — low bankruptcy risk

Market CapQuality
$113.95B9/10

Large-cap with strong market position

Return on EquityProfitability
22.5%9/10

Every $100 of equity generates 23 in profit

Debt/EquityHealth
0.219/10

Conservative balance sheet, low leverage

Areas to Watch

BE4 concerns · Avg: 2.3/10
Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

PEG RatioValuation
4.272/10

Expensive relative to growth rate

Price/BookValuation
48.5x2/10

Trading at 48.5x book value

Return on EquityProfitability
-12.7%2/10

ROE of -12.7% — below average capital efficiency

VRTX3 concerns · Avg: 3.7/10
PEG RatioValuation
2.194/10

Expensive relative to growth rate

P/E RatioValuation
29.3x4/10

Moderate valuation

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Comparative Analysis Report

WallStSmart Research

Bull Case : BE

The strongest argument for BE centers on Revenue Growth. Revenue growth of 35.9% demonstrates continued momentum.

Bull Case : VRTX

The strongest argument for VRTX centers on Profit Margin, Operating Margin, Altman Z-Score. Profitability is solid with margins at 32.9% and operating margin at 39.6%.

Bear Case : BE

The primary concerns for BE are Piotroski F-Score, PEG Ratio, Price/Book.

Bear Case : VRTX

The primary concerns for VRTX are PEG Ratio, P/E Ratio, Piotroski F-Score.

Key Dynamics to Monitor

BE profiles as a hypergrowth stock while VRTX is a mature play — different risk/reward profiles.

BE carries more volatility with a beta of 3.18 — expect wider price swings.

BE is growing revenue faster at 35.9% — sustainability is the question.

BE generates stronger free cash flow (398M), providing more financial flexibility.

Bottom Line

VRTX scores higher overall (66/100 vs 35/100), backed by strong 32.9% margins. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Bloom Energy Corp

INDUSTRIALS · ELECTRICAL EQUIPMENT & PARTS · USA

Bloom Energy Corporation designs, manufactures and sells solid oxide fuel cell systems for on-site power generation in the United States, Japan, China, India, and the Republic of Korea. The company is headquartered in San Jose, California.

Vertex Pharmaceuticals Inc

HEALTHCARE · BIOTECHNOLOGY · USA

Vertex Pharmaceuticals, Inc. is an American biopharmaceutical company based in Boston, Massachusetts.

Want to dig deeper into these stocks?